Synosia Therapeutics Announces Appointment of Chief Business Officer

    SAN FRANCISCO, Dec. 13 /CNW/ - Synosia Therapeutics today announced the
appointment of Antony Blanc, Ph.D., as the company's new chief business
officer, effective immediately.
    Dr Blanc, who will serve as head of Synosia's office in Basel,
Switzerland, joins from Syngenta, where he created and led the
biopharmaceuticals business unit. A molecular biologist by training and an
experienced biotech entrepreneur, Dr. Blanc helped biotech and pharma clients
with R&D, commercial and strategy issues as associate partner with the
business consultants McKinsey & Company.
    "With a strong entrepreneurial flair in biotech and expertise in both
science and business, Antony Blanc brings together the skills we need to lead
our increasingly important presence in Switzerland," said Synosia Chief
Executive Officer and President Dr. Ian Massey. "Our three pharmaceutical
partners are based in Basel and this appointment will give us the leadership
we need in Europe to meet our ambitious goals for 2008, including the start of
four phase II trials."
    "Synosia has a broad clinical-stage portfolio with several advanced
molecules, highly experienced leaders, a well-aligned and strong investor base
and a grounding in both the US and in Switzerland. I look forward to building
on this promising combination to create a leading CNS-focused specialty pharma
company" said Blanc.
    Antony Blanc replaces Herve Girsault M.B.A., who will remain on Synosia's
board of directors and continue to act as a key business advisor to the

    About Synosia Therapeutics

    Synosia Therapeutics develops and intends to commercialize innovative and
clinically differentiated products for unmet medical needs in psychiatry and
neurology. The privately-owned company is developing six clinical-stage
compounds acquired through key partnerships with Novartis, Roche and Syngenta,
including two marketed drugs that will be tested in new indications, extending
their reach into new therapeutic areas with combined sales potential in excess
of US$2.5 billion. Synosia has offices in Basel, Switzerland, and South San
Francisco, CA.
    Synosia Therapeutics has raised US$32.5 million funding from Versant
Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo
Park, CA) and Novo A/S (Copenhagen, Denmark). For more information, visit

For further information:

For further information: In Europe: Julie Walters at Media Speak, Tel:
+44(0)1494-753-990, Mobile +44(0)775-3626967,; In
US: Michele Parisi at Media Speak, Tel: (925) 864-5028,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890